GlassScriptPhysician profile
Molly Bradish Degroh
NPI 1942020755
$487.67
in general payments reported to CMS, 2019-2025
11 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $6.91 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $117.14 | 2025 | Zurzuvae |
| Novo Nordisk INC | $93.82 | 2025 | Wegovy |
| Hologic Sales and Service, LLC | $43.09 | 2025 | Myosure Tissue Removal Device, Aptima |
| Exeltis, USA INC. | $37.92 | 2025 | Slynd |
| Millicent US INC | $35.86 | 2025 | Femlyv, Intrarosa |
| Smith+Nephew, INC. | $34.04 | 2025 | Stravix Pl |
| Mayne Pharma Commercial LLC | $33.30 | 2024-2025 | |
| Pfizer INC. | $30.13 | 2025 | |
| Becton, Dickinson and Company | $30.00 | 2025 | |
| Astellas Pharma US INC | $18.85 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $13.52 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Degroh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.